SAN DIEGO, May 25, 2017 /PRNewswire/ -- MabVax
Therapeutics Holdings, Inc. (Nasdaq: MBVX), a clinical-stage
biotechnology company with a fully human antibody discovery
platform focused on the rapid translation into clinical development
of products to address unmet medical needs in the treatment of
cancer, announced today that results from the Phase I clinical
trial of MabVax's therapeutic antibody MVT-5873, being evaluated in
advanced pancreatic cancer and other CA19-9 positive cancers, will
be presented in a poster presentation at the American Society of
Clinical Oncology (ASCO) Annual Meeting to be held in Chicago, IL, June 2 -
6, 2017.
As part of the presentation, MabVax will discuss the results of
the Company's dose-escalation and safety trial, conducted over the
last year in 32 patients with advanced pancreatic and colon cancer.
Additionally, single agent MVT-5873 safety profile, efficacy, and
reductions in serum CA19-9 levels over time will be
presented.
Title of Presentation: Single agent HuMab-5B1
(MVT-5873), a monoclonal antibody targeting sLea, in patients with
pancreatic cancer and other CA19-9 positive
malignancies.
Abstract Number: 4110
Location: Gastrointestinal (Non-colorectal) Cancer
Session
Session Date: Saturday, June
3rd
Time: 8:00 AM to 11:30 AM
(CDT)
The Phase I therapeutic trial is an open-label, dose-escalation
study evaluating the safety, tolerability and pharmacokinetics of
MVT-5873. The first group of patients enrolled assess safety and
determined the recommended Phase II dose of the antibody. The
second patient group will establish the safety and dose of the
antibody when administered with a standard-of-care chemotherapy.
Dr. Eileen O'Reilly, associate
Director of the David M. Rubenstein Center for Pancreatic Cancer
Research, attending physician, member at Memorial Sloan Kettering
Cancer Center and Professor of Medicine at Weill Cornell Medical
College is the lead investigator in the MVT-5873 Phase I clinical
trial.
About MabVax Therapeutics Holdings, Inc.
MabVax Therapeutics Holdings, Inc. is a clinical-stage
biotechnology company with a fully human antibody discovery
platform focused on the rapid translation into clinical development
of products to address unmet medical needs in the treatment of
cancer. Our lead antibody is directed at an antigen target
expressed on more than 90% of pancreatic cancers and a significant
amount of other GI and lung cancers, making the antibody
potentially broadly applicable to a wide variety of patients
suffering from difficult to treat cancers. With our collaborators
including Memorial Sloan Kettering Cancer Center, Rockefeller University, Sarah Cannon, Honor Health and Imaging
Endpoints, we have treated 50 patients with either our therapeutic
antibody designated as MVT-5873 or our PET imaging diagnostic
product designated as MVT-2163 in Phase I clinical studies, and
demonstrated early safety, specificity for the target and an early
efficacy signal. Results of these trials should be published by
mid-year 2017. Additionally, our Phase I clinical study of our
radioimmunotherapy product designated as MVT-1075 has been
authorized to proceed by the FDA and will soon commence with
patient enrollment. For additional information, please visit the
Company's website, www.mabvax.com.
Forward Looking Statements:
This press release contains "forward-looking statements"
regarding matters that are not historical facts, including
statements relating to presentations at the ASCO Annual
Meeting. We have no assurance that all the product development
pipeline will be fully developed by the Company. Because such
statements are subject to risks and uncertainties, actual results
may differ materially from those expressed or implied by such
forward-looking statements. Words such as "anticipates,"
"plans," "expects," "intends," "will," "potential," "hope" and
similar expressions are intended to identify forward-looking
statements. These forward-looking statements are based upon current
expectations of the Company and involve assumptions that may never
materialize or may prove to be incorrect. Actual results and
the timing of events could differ materially from those anticipated
in such forward-looking statements because of various risks and
uncertainties. Detailed information regarding factors that may
cause actual results to differ materially from the results
expressed or implied by statements in this press release relating
to the Company may be found in the Company's periodic filings with
the Securities and Exchange Commission, including the factors
described in the section entitled "Risk Factors" in its annual
report on Form 10-K for the fiscal year ended December 31, 2016, as amended and supplemented
from time to time and the Company's Quarter Reports on Form
10-Q and other filings submitted by the Company to the SEC, copies
of which may be obtained from the SEC's website
at www.sec.gov. The parties do not undertake any obligation to
update forward-looking statements contained in this press
release.
Investor Contact:
Jenene Thomas
Jenene Thomas Communications, LLC
Phone: +1 (908) 938-1475
Email: jtc@jenenethomascommunications.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/mabvax-therapeutics-to-present-phase-i-clinical-trial-results-of-mvt-5873-for-the-treatment-of-advanced-pancreatic-cancer-in-poster-presentation-at-the-2017-asco-annual-meeting-300462602.html
SOURCE MabVax Therapeutics Holdings, Inc.